Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price at the time of the transaction: 1350.50 pence per Ordinary Share and $41.36 per American Depositary Share (ADS).
Material Changes
There are no material changes to the company's financial position or operations reported in this filing. The document details increases in the notional interests of specific Directors and PDMRs resulting from the re-investment of dividends paid on shares held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of insider share acquisitions.
Key Facts for Investor Verification
- Transaction Type: Acquisitions of Ordinary Shares and ADSs via dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Transaction Price: 1350.50 pence per Ordinary Share; $41.36 per ADS.
- Participants: Includes CEO Sir Andrew Witty and other senior executives (e.g., Dr. P J T Vallance, Dr. M M Slaoui).
- Acquisition Structure: Shares were acquired under both the personal contribution element and the matching element (GSK contribution) of the plan.
- Financial Data: No revenue, earnings, or balance sheet data is included in this specific report.